Osteoarthritis is highly heterogeneous, so effective therapies will need to target clearly defined molecular endotypes, restore mechanical joint function and reduce pain; thus, a ‘one-size-fits-all’ approach is unlikely to succeed.
References
Cui, A., Li, H., Wang, D., Zhong, J., Chen, Y. & Lu, H. EClinicalMedicine 29-30, 100587 (2020).
van den Bosch, M. H. J. Osteoarthritis year in review 2020: biology. Osteoarthritis Cartilage 29, 143–150 (2021).
Gerwin, N. et al. Nat. Med. https://doi.org/10.1038/s41591-022-02059-9 (2022).
Deveza, L. A., Nelson, A. E. & Loeser, R. F. Clin. Exp. Rheumatol. 37, 64–72 (2019). suppl. 120.
Oo, W. M., Little, C., Duong, V. & Hunter, D. J. Drug Des. Devel. Ther. 15, 2921–2945 (2021).
Oo, W. M. & Hunter, D. J. Ther. Adv. Musculoskelet. Dis. 14, 1759720X221090297 (2022).
Burr, D. B. & Gallant, M. A. Nat. Rev. Rheumatol. 8, 665–673 (2012).
Schäfer, N. & Grässel, S. Peptides 154, 170815 (2022).
Fu, K., Robbins, S. R. & McDougall, J. J. Rheumatology 57, iv43–iv50 (2018).
Schmelz, M. et al. Pain 160, 2210–2220 (2019).
Krupka, E., Jiang, G. L. & Jan, C. Osteoarthritis Cartilage 27, 1599–1607 (2019).
Grässel, S. & Muschter, D. F1000Res 9, 325 (2020).
Acknowledgements
This work was supported by the German Research Society (DFG; grant number GR 1301/22-1, assigned to S.G.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Schäfer, N., Grässel, S. Targeted therapy for osteoarthritis: progress and pitfalls. Nat Med 28, 2473–2475 (2022). https://doi.org/10.1038/s41591-022-02057-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02057-x
- Springer Nature America, Inc.